Creating new drugs to fight chemotherapy-resistant triple negative breast cancer
Official title: Developing novel LOX inhibitors to target chemotherapy resistant TNBC
Funded at Loxigen, INC. · NIH-11116003 · Data updated 2026-11-12
This study is working on new medications that can help make chemotherapy more effective for people with triple negative breast cancer by targeting a protein called lysyl oxidase, which can make tumors resistant to treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Loxigen, INC. NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project start | June 8, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $992,932 |
| NIH project number | 4R42CA275622-02 |
| Project ID | NIH-11116003 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have experienced resistance to conventional chemotherapy.
✕Less likely to help
Patients with non-breast cancer types or those who have not undergone chemotherapy may not benefit from this research.
What this research studies
This research focuses on developing new inhibitors that target lysyl oxidase (LOX), a protein linked to chemotherapy resistance in triple negative breast cancer (TNBC). The project aims to create effective and safe LOX inhibitors that can help re-sensitize aggressive breast tumors to chemotherapy treatments. By using advanced screening techniques, the researchers will identify compounds that specifically engage LOX and have favorable properties for oral administration. This approach seeks to improve treatment outcomes for patients who currently have limited options due to resistance.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with chemotherapy-resistant triple negative breast cancer.
How similar studies have gone: Previous research has shown promise in targeting LOX for overcoming chemotherapy resistance, indicating that this approach has potential based on earlier findings.
Where this research is happening
-
Loxigen, INC.
Charleston, United States Active
Researchers
- Principal investigator: Sahin, Ozgur — Loxigen, INC.
- Study coordinator: Sahin, Ozgur
Related research
Other NIH-funded projects on the same topics.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
A 3D ultrasound scanner to see early chemotherapy response in breast cancer
A new 3D ultrasound imaging method will be tested to see if it can quickly show whether breast cancer is responding to chemotherapy.
-
Non-invasive, microscopic biomarkers to detect CIPN in chemotherapy patients
This grant aims to develop a non-invasive imaging method to measure nerve changes in patients undergoing chemotherapy to better understand and monitor chemotherapy-induced peripheral neuropathy (CIPN).
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.